The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Trufanov S.V.

Research Institute of Eye Diseases

Malozhen S.A.

Krasnov Research Institute of Eye Diseases

Krakhmaleva D.A.

Research Institute of Eye Diseases

Surnina Z.V.

Krasnov Research Institute of Eye Diseases

Pivin E.A.

Research Institute of Eye Diseases

Kasparova E.A.

Krasnov Research Institute of Eye Diseases

Antiangiogenic therapy in high-risk keratoplasty

Authors:

Trufanov S.V., Malozhen S.A., Krakhmaleva D.A., Surnina Z.V., Pivin E.A., Kasparova E.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2020;136(4): 11‑18

DOI: 10.17116/oftalma202013604111

Read: 2007 times

Download PDF (RU)
Contact the author
Table of contents

ANTIANGIOGENIC THERAPY IN HIGH-RISK KERATOPLASTY
ANTIANGIOGENIC THERAPY IN HIGH-RISK KERATOPLASTY

To cite this article:

Trufanov SV, Malozhen SA, Krakhmaleva DA, Surnina ZV, Pivin EA, Kasparova EA. Antiangiogenic therapy in high-risk keratoplasty. Russian Annals of Ophthalmology. 2020;136(4):11‑18. (In Russ.)
https://doi.org/10.17116/oftalma202013604111

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

PURPOSE

To analyze the effectiveness and safety of VEGF inhibitor used to improve keratoconus transplant survival in patients with corneal neovascularization as stand-alone and in combination with laser coagulation of ingrowing vessels before keratoplasty.

MATERIAL AND METHODS

The study included 56 patients (56 eyes) with corneal opacifications of various etiology complicated by corneal neovascularization (CNV). The patients were divided into three groups. The 1st group included 27 patients with diffuse CNV who were undergoing an antiangiogenic therapy using anti-VEGF drug, the 2nd group — 14 patients with stem cell CNV who underwent laser coagulation of major corneal vessels combined with subconjunctival administration of drug before keratoplasty; the control group consisted of 15 patients with mixed type CNV who were undergoing conventional treatment without antiangiogenic therapy.

RESULTS

During the follow-up (24.5±4.84 months, 4 to 25 months), transplant rejection reaction was recorded in 7 (23%) patients of the 1st group, 5 (35%) patients of the 2nd group and 9 (60%) patients of the control group.

CONCLUSION

Subconjunctival administration of Aflibercept as a stand-alone measure and in combination with laser coagulation of ingrowing vessels may increase the chances of transparent transplant acceptance in high-risk keratoplasty.

Keywords:

high-risk keratoplasty
corneal neovascularization
VEGF inhibitor
laser coagulation of ingrowing vessels of the cornea
reaction of transplant rejection

Authors:

Trufanov S.V.

Research Institute of Eye Diseases

Malozhen S.A.

Krasnov Research Institute of Eye Diseases

Krakhmaleva D.A.

Research Institute of Eye Diseases

Surnina Z.V.

Krasnov Research Institute of Eye Diseases

Pivin E.A.

Research Institute of Eye Diseases

Kasparova E.A.

Krasnov Research Institute of Eye Diseases

Received:

07.06.2019

Accepted:

17.12.2019

Close metadata

References:

  1. Niederkorn JY, Larkin FP. Immune Privilege of Corneal Allografts. Ocul Immunol Inflamm. 2010;18(3):162-171.  https://doi.org/10.3109/09273948.2010.486100
  2. Qazi Y, Pedram Hamrah P. Corneal Allograft Rejection: Immunopathogenesis to Therapeutics. J Clin Cell Immunol. 2013;9:006.  https://doi.org/10.4172/2155-9899.s9-006
  3. Nirankari VS, Dandona L, Rodrigues MM. Laser Photocoagulation of Experimental Corneal Stromal Vascularization. Ophthalmology. 1993;100(1): 111-118.  https://doi.org/10.1016/s0161-6420(93)31706-9
  4. Cursiefen C. Immune Privilege and Angiogenic Privilege of the Cornea. Chem Immunol Allergy. 2007;92:50-57.  https://doi.org/10.1159/000099253
  5. Vassileva PI, Hergeldzhieva TG. Avastin use in high risk corneal transplantation. Graefes Arch Clin Exp Ophthalmol. 2009;247:1701-1706.
  6. Voevodina TM, Fedorov AA, Budzinskaia MV. Current methods of anti-angiogenic influence on newly formed corneal vessels. Vestnik oftal’mologii. 2013;129(3):98-101. (In Russ.).
  7. Ferrari G, Dastjerdi M, Okanobo A, et al. Topical Ranibizumab as a Treatment of Corneal Neovascularization. Cornea. 2013;32(7):992-997.  https://doi.org/10.1097/ico.0b013e3182775f8d
  8. Stevenson W, Cheng S, Dastjerdi M, Ferrari G, Dana R. Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) Vs Bevacizumab (Avastin). Ocular Surface. 2012;10(2):67-83.  https://doi.org/10.1016/j.jtos.2012.01.005
  9. Kang S, Choi H, Rho CR. Differential Effects of Bevacizumab, Ranibizumab, and Aflibercept on the Viability and Wound Healing of Corneal Epithelial Cells. J Ocul Pharmacol Ther. 2016;32(10):671-676.  https://doi.org/10.1089/jop.2016.0094
  10. Petsoglou C, Balaggan K, Dart J, Bunce C, Xing W, Ali R, et al. Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. Brit J Ophthalmol. 2012;97(1):28-32.  https://doi.org/10.1136/bjophthalmol-2012-302137
  11. Mamikonian VR, Voevodina TM, Fedorov AA, Budzinskaia MV, Balaian ML. Experimental and morphological study of the effect of antiangiogenic therapy on corneal neovessels. Vestnik oftal’mologii. 2013;129(6):45-50. (In Russ.).
  12. Krakhmaleva DA, Malozhen SA, Mamikonian VR, Pivin EA, Trufanov SV. Efficacy of combined use of anti-VEGF (Aflibertsept) and lasercoagulation for corneal neovascularisation before keratoplasty. Klinicheskaia praktika. 2018;33(1):36-39. (In Russ.).
  13. Voino-Yasenetskii VV. Tkanevaya nesovmestimost’ i puti ee preodoleniya [Tissue incompatibility and ways to overcome it]. M.: Meditsina; 1971. (In Russ.).
  14. Resch M, Marsovszky L, Németh J, Bocskai M, Kovács L, Balog A. Dry Eye and Corneal Langerhans Cells in Systemic Lupus Erythematosus. J Ophthalmol. 2015;2015:1-8.  https://doi.org/10.1155/2015/543835
  15. Dastjerdi M, Saban D, Okanobo A, et al. Effects of Topical and Subconjunctival Bevacizumab in High-Risk Corneal Transplant Survival. Invest Ophthalmol Vis Sci. 2010;51(5):2411. https://doi.org/10.1167/iovs.09-3745
  16. Dekaris I, Gabrić N, Drača N, Pauk-Gulić M, Miličić N. Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2015;253(2):287-294.  https://doi.org/10.1007/s00417-014-2851-8
  17. Fasciani R, Mosca L, Giannico MI, Ambrogio SA, Balestrazzi E. Subconjunctival and/or intrastromal bevacizumab injections as preconditioning therapy to promote cornealgraft survival. Int Ophthalmol. 2015;35(2):221-227.  https://doi.org/10.1007/s10792-014-9938-4
  18. Bhatti N, Qidwai U, Hussain M, Kazi A. Efficacy of sub-conjunctival and topical bevacizumab in high-risk corneal transplant survival. J Pak Med Assoc. 2013;63(10):1256-1259.
  19. Bhatti N, Qidwai U, Hussain M, Kazi A. Efficacy of topical bevacizumab in high-risk corneal transplant survival. Pak J Med Sci. 2013;29(2):519-522.  https://doi.org/19.0.12669/pjms.292.3089
  20. Niederer LR, Sherwin T, McGhee CNJ. In vivo confocal microscopy of subepithelial infiltrates in human corneal transplant rejection. Cornea. 2007; 26:501-504.  https://doi.org/20.10.1097/ICO.0b013e3180318107
  21. Mamikonyan VR, Pivin EA, Krakhmaleva DA. Mechanisms and modern features of corneal neovascularisation suppression. Vestnik oftal’mologii. 2016;132(4):70-76. (In Russ.). https://doi.org/10.17116/oftalma2016132470-76
  22. Chauhan KS. Corneal Lymphatics: Role in Ocular Inflammation as Inducer and Responder of Adaptive Immunity. J Clin Cell Immunol. 2014;5:256.  https://doi.org/10.4172/2155-9899.1000256
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.